Translation

Notice:	This document is a translation of the original Japanese document and is for reference purposes only. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

November 7, 2024
Alfresa Holdings Corporation

Notice regarding the Determination of Matters Concerning Share Buyback

At the Board of Directors' meeting held on November 7, 2024, Alfresa Holdings Corporation resolved to buyback shares of the Company, pursuant to the provisions of article 459, paragraph 1 of the Companies Act, as well as the provisions of article 46 of the Company's Articles of Incorporation, as follows.

1. Reason for the Share Buyback

Under the Company's 22-24 Mid-term Management Plan, the Company aims to achieve a three-year cumulative total shareholder return ratio of 100%. Based on this goal, and to improve capital efficiency and enhance shareholder returns, the Company will acquire treasury stock in a flexible manner.

2. Details of Matters concerning the Purchase

(1)	Type of stock acquired	Common stock
(2)	Total number of shares that can be acquired	6,000,000 shares (maximum) (Ratio to the number of outstanding shares (excluding treasury stock): 3.2%)
(3)	Total acquisition value of shares	11.0 billion yen (maximum)
(4)	Acquisition period	From Nov 8, 2024, through May 30, 2025
(5)	Acquisition method	Market purchases on the Tokyo Stock Exchange

(Reference) Treasury Stock Holdings as of September 30, 2024

Number of shares outstanding (excluding treasury stock)	187,317,770 shares
Number of treasury stock	15,522,230 shares

Note: The Company's 414,832 shares held by the Board Incentive Plan trust are not included in the treasury stock.

About the Alfresa Group

The Alfresa Group is a leader in the Japanese healthcare industry and is dedicated to making its corporate philosophy, "we create and deliver a fresh life for all," come true through a wide range of business lines, including ethical pharmaceuticals wholesaling, OTC pharmaceuticals

wholesaling, pharmaceutical manufacturing, and operating dispensing pharmacies. Alfresa Holdings Corporation (TSE:2784) reported consolidated revenue of ¥2.8 trillion for the fiscal year ended March 31, 2024. For more information, please see: https://www.alfresa.com/eng/